A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia

Published:2019-12-20 Issue:6 Volume:126 Page:1264-1273
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Narayan Rupa¹^ORCID,Blonquist Traci M.²,Emadi Ashkan³^ORCID,Hasserjian Robert P.¹,Burke Meghan¹,Lescinskas Christopher¹^ORCID,Neuberg Donna S.²,Brunner Andrew M.¹,Hobbs Gabriela¹,Hock Hanno¹,McAfee Steven L.¹,Chen Yi‐Bin¹,Attar Eyal¹,Graubert Timothy A.¹,Bertoli Christina¹,Moran Jenna A.¹,Bergeron Meghan K.¹,Foster Julia E.¹,Ramos Aura Y.¹,Som Tina T.¹,Vartanian Megan K.¹,Story Jennifer L.¹,McGregor Kristin¹,Macrae Molly¹,Behnan Tanya¹,Wey Margaret C.¹,Rae Jessica¹,Preffer Frederic I.¹,Lesho Patricia³,Duong Vu H.³,Mann Mason L.¹,Ballen Karen K.¹,Connolly Christine¹,Amrein Philip C.¹,Fathi Amir T.¹^ORCID

Affiliation:

1. Division of Hematology/Oncology Massachusetts General Hospital Boston Massachusetts

2. Division of Biostatistics Dana‐Farber Cancer Institute Boston Massachusetts

3. Division of Hematology/Oncology University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center Baltimore Maryland

Funder

Seattle Genetics

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32657

Reference28 articles.

1. Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

2. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience

3. Is there a standard of care for relapsed AML?

4. Mitoxantrone, cytosine arabinoside, and VP‐16 in 36 patients with relapsed and refractory acute myeloid leukemia;Link H;Haematol Blood Transfus,1990

5. Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Nonlymphocytic Leukemia

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies;British Journal of Clinical Pharmacology;2024-06-23

2. Can Nitric Oxide-Based Therapy Be Improved for the Treatment of Cancers? A Perspective;International Journal of Molecular Sciences;2023-09-02

3. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia;European Journal of Medical Research;2023-03-20

4. A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors;Biomaterials Science;2023

5. Natural killer cells and acute myeloid leukemia: promises and challenges;Cancer Immunology, Immunotherapy;2022-05-31